A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed By an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer.

Trial Profile

A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed By an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Letrozole (Primary)
  • Indications Breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 20 Apr 2010 Novartis added as trial sponsor, additional lead trial centre and actual patient number (3966) as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Planned end date changed from 1 Oct 2015 to 1 Oct 2018 as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top